Concepedia
Statistics
Publications
11
Citations
1.3K
H-Index
10
Active since
2011
Affiliations
Eli Lilly (United States)(Current)
Loxo Oncology at Lilly (United States)
Eli Lilly (Spain)
Lilly (China)
Lysiane Huber is an author at Eli Lilly (United States) specializing in oncology, medicine, and pharmacology.
Publications per year
2011–2024
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text
Medicine, Immunology, Pharmacology +17
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text
Medicine, Cancer Biology, Oncology +16
Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn et al. · Cancer Discovery · 2016 · 172 citations
Life Sciences, Molecular Biology, Oncology +15
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Vipin Yadav, Teresa F. Burke, Lysiane Huber et al. · Molecular Cancer Therapeutics · 2014 · 135 citations
Medicine, Oncology, Pharmacology +16
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana, Susan E. Pratt, Wayne Blosser et al. · Oncotarget · 2016 · 69 citations · Full text
Medicine, Oncology, Pharmacology +17
1–5 of 11